14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
EXAS vs TEM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EXAS Overall Winner
6-Pillar Tally: EXAS 5 – 1 TEM
Matrix Metrics: EXAS 7 – 0 TEM
As of Nov 17, 2026, Exact Sciences Corp (EXAS) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EXAS carries a Unified Composite Score of 59.1/100 (HOLD) at $104.91 (N/M Forward P/E, -9.3% operating margin), whereas TEM carries 43.5/100 (HOLD) at $63.43 (N/M Forward P/E, -18.5% operating margin).
Technical & Structure Timing Caution: EXAS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 75.9); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EXAS vs TEM. Trailing 12-month operating profitability (EXAS -9.3% vs TEM -18.5%) and valuation multiples (EXAS N/M vs TEM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Diagnostics & Research value chain with $19.8B market capitalization and -9.3% operating margin.
OpEx & R&D Reinvestment79.0% of Rev ($2.57B)
90D Engineering Disclosures0 Published
TEM Moat ProfileEcosystem & Network-Effect Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $13.1B market capitalization and -18.5% operating margin.
OpEx & R&D Reinvestment83.0% of Rev ($1.25B)
90D Engineering Disclosures0 Published · AI Drug Discovery
Investor FAQ EXAS vs TEM Key Questions & Quantitative Answers
As of Nov 17, 2026, Exact Sciences Corp (EXAS) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EXAS carries a Unified Composite Score of 59.1/100 (HOLD) at $104.91 (N/M Forward P/E, -9.3% operating margin), whereas TEM carries 43.5/100 (HOLD) at $63.43 (N/M Forward P/E, -18.5% operating margin). Technical & Structure Timing Caution: EXAS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 75.9); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EXAS leads the Growth & Scale pillar: EXAS posts +23.1% YoY revenue growth and +0.0% YoY earnings growth on $3.25B TTM revenue (69.7% gross margin, -9.3% operating margin), compared with TEM at +23.1% YoY revenue growth and +0.0% YoY earnings growth on $1.51B TTM revenue (64.5% gross margin, -18.5% operating margin). On trailing 12-month operating scale, EXAS generates $3.25B in USD-normalized revenue versus $1.51B for TEM. In operating R&D and SG&A reinvestment, EXAS deploys 79.0% of Rev ($2.57B) (0 90-day corporate R&D disclosures) versus 83.0% of Rev ($1.25B) (0 disclosures) for TEM.
EXAS screens cheaper on headline valuation multiples. EXAS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.1x EV/Revenue (2.2% EBITDA margin), whereas TEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (-10.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EXAS (-8.7% ROE) versus TEM (-37.5% ROE) capital efficiency.
In options market volatility and institutional positioning, EXAS carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.05β · 4% Vol realized risk). By comparison, TEM carries 99.3% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.51β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.